Publicaciones (62) Publicaciones de RAFAEL SEGARRA ECHEVARRIA

2024

  1. Clinical Predictors of Mood Disorders and Prevalence of Neuropsychiatric Symptoms in Patients with Systemic Lupus Erythematosus

    Journal of Clinical Medicine, Vol. 13, Núm. 18

  2. Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis

    Therapeutic Advances in Psychopharmacology, Vol. 14

  3. Emotional intelligence and neurocognition profiles in first-episode psychosis: A two-year follow-up study

    European Neuropsychopharmacology, Vol. 85, pp. 66-77

  4. Gender sensitivity of the COVID-19 mental health research in Europe: a scoping review

    International Journal for Equity in Health, Vol. 23, Núm. 1

  5. Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study

    Spanish Journal of Psychiatry and Mental Health

2023

  1. Clinical Management and Assessment of the Early Stages of Psychosis: A Multidimensional Approach

    Methods in molecular biology (Clifton, N.J.), Vol. 2687, pp. 141-150

  2. First-episode psychosis intervention programme versus standard care for the clinical management of early phases of psychosis: Cost analysis

    BJPsych Open, Vol. 10, Núm. 1

  3. Gender differences in the management of acute psychiatric episodes in the emergency department: a cross-sectional analysis of the 2017–2019 triennium

    Archives of Women's Mental Health, Vol. 26, Núm. 6, pp. 777-783

  4. Isolation and Differentiation of Neurons and Glial Cells from Olfactory Epithelium in Living Subjects

    Molecular Neurobiology, Vol. 60, Núm. 8, pp. 4472-4487

  5. Letter to the editor: Gwinnutt JM, Toyoda T, Barraclough M, Verstappen SMM, Hornberger M, MacGregor A. Cognitive impairment in the immune-mediated inflammatory diseases compared with age-matched controls: Systematic review and meta-regression

    Seminars in Arthritis and Rheumatism

  6. Neuropsychological and Functional Assessment of Cognitive Impairments in Schizophrenia

    Methods in molecular biology (Clifton, N.J.), Vol. 2687, pp. 127-139

  7. Psychosis and substance abuse increase the COVID-19 mortality risk

    Psychological Medicine, Vol. 53, Núm. 9, pp. 4236-4244

  8. Violence in first-episode psychosis: Evidence from an early intervention in psychosis programme

    BJPsych Open, Vol. 9, Núm. 5

2022

  1. Relation between EEG resting-state power and modulation of P300 task-related activity in theta band in schizophrenia

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 116

2021

  1. Characterization of dopamine D2 receptor coupling to G proteins in postmortem brain of subjects with schizophrenia

    Pharmacological Reports, Vol. 73, Núm. 4, pp. 1136-1146

  2. Cognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptoms

    Frontiers in Psychiatry, Vol. 12

  3. Gender-Based Analysis of the Psychological Impact of the COVID-19 Pandemic on Healthcare Workers in Spain

    Frontiers in Psychiatry, Vol. 12

  4. Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report

    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, Vol. 11

  5. Oral and Palmitate Paliperidone Long-Acting Injectable Formulations' Use in Schizophrenia Spectrum Disorders: A Retrospective Cohort Study from the First Episode Psychosis Intervention Program (CRUPEP)

    International Journal of Neuropsychopharmacology, Vol. 24, Núm. 9, pp. 694-702

2020

  1. Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study

    Schizophrenia Research, Vol. 218, pp. 292-294